SciSparc shares are trading higher after the company submitted an Investigational New Drug (IND) application to the FDA for SCI-110.
Portfolio Pulse from Benzinga Newsdesk
SciSparc shares rose following the submission of an Investigational New Drug (IND) application to the FDA for their drug candidate SCI-110.
August 23, 2024 | 8:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SciSparc's stock price increased after the company submitted an IND application to the FDA for SCI-110, indicating potential progress in their drug development pipeline.
The submission of an IND application is a significant step in drug development, suggesting potential future growth and progress in SciSparc's pipeline. This news likely increased investor confidence, leading to a rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100